[Skip to content]

Quality care, when and when you need it
Southern Health NHS Foundation Trust
Search options
.

Memory Assessment and Research Centre (MARC) 

Committed to research

MARC's logo

MARC is one of the leading centres in Europe for dementia research: Dr David Wilkinson and Professor Clive Holmes are internationally renowned for their expertise in this area.

Our long-term commitment to research means we have one eye on the future but are just as concerned with helping you live day-to-day. We understand as a carer or relative, the condition affects you too. MARC is here to provide access to support and advice as we know what a huge impact this illness can have. 

Get Involved

If you or someone you know has Alzheimer's disease and are interested in getting involved in research, this website will help you find out about what it entails and the latest trials taking place at MARC.

 

Trials Now Recruiting

 This is a four month long trial.

Investigating the effectiveness and safety of memantine in the treatment of memory, concentration or attention problems in the absence of dementia. Participants need to be aged between 50 and 80. There is no specific MMSE score or mild cognitive impairment diagnosis needed.  

This is a 26 week long trial.

The purpose of the trial is to find out whether a drug called tideglusib is safe and effective for people with Alzheimer’s disease. Those who participate need to be aged between 40 and 85 and have a MMSE from 14 to 26.

A six month long trial.

The purpose of the trial is to find out whether a drug called etanercept is safe and well tolerated in patients with Alzheimer's disease. Etanercept is a medicine used for illnesses where parts of the body become inflamed. It is already used safely in over 8000 people a year in the UK who suffer from Rheumatoid Arthritis.

In Alzheimer's disease the brain becomes inflamed. We want to see if etanercept can be used to reduce inflammation, and so reduce the symptoms of the disease.

This is a six month study with only two home visits.

This study aims to develop a questionnaire that measures the way behaviour changes in someone with Alzheimer’s disease. This study does not involve any extra medication. Those who participate need to be 65 years or older and have a MMSE score between 10 and 27.